Fig. 1: MEF2A was increased in CRC tissues, cetuximab-resistant CRC tissues, as well as CRC cell lines. | Cell Death Discovery

Fig. 1: MEF2A was increased in CRC tissues, cetuximab-resistant CRC tissues, as well as CRC cell lines.

From: N6-methyladenosine modification of MEF2A weakens cetuximab sensitivity in colorectal cancer via PD-L1/SOX12 axis

Fig. 1

CRC patients (n = 20, including 8 cetuximab-sensitive and 12 cetuximab-resistant specimens) were recruited for the collection of cancerous tissues and adjacent non-cancerous tissues. RT-qPCR for measuring MEF2A mRNA levels in normal tissues and cancerous tissues (A), as well as in cetuximab-resistant and cetuximab-sensitive CRC tissues (B). MEF2A protein level in clinical samples was detected with immunohistochemistry. Scale bar: 50 μm and 10 μm (C). D The association between 3-year and 5-year survival rates of CRC patients and MEF2A level showed by bioinformatics analysis (Kaplan–Meier Plotter). E In normal colonic epithelial cell line (FHC) and CRC cell lines (HCT 116, SW480, SW620, Caco-2, and LoVo), MEF2A protein levels were determined with western blot. All bar chart analysis of western blot is a repeated experiment three times. *p < 0.05, **p < 0.01, and ***p < 0.001.

Back to article page